



NDA 202971/S-018
NDA 217006/S-001

SUPPLEMENT APPROVAL

Otsuka Pharmaceutical Company, Ltd.
c/o Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention: Onjee Choi, PhD
Associate Director, Global Regulatory Affairs
508 Carnegie Center Drive
Princeton, NJ 08540

Dear Dr. Choi:

Please refer to your supplemental new drug applications (sNDAs) dated and received May 30, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Abilify Maintena (aripiprazole) for extended-release injectable suspension, and Abilify Asimtufii (aripiprazole) extended-release injectable suspension.

These Prior Approval supplemental new drug applications provide for a 1-day initiation regimen to the Prescribing Information as an additional option for treatment initiation.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://www.fda.gov).¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry, *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA; 21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Regarding NDA 202971, we are waiving the pediatric studies requirement for this application because the product fails to represent a meaningful therapeutic benefit and is unlikely to be used in a substantial number of patients for the management of maintenance treatment of schizophrenia. In addition, recruiting pediatric patients for a placebo-controlled maintenance trial would be difficult. Schizophrenia is less common in children and adolescents than in adults. The onset of schizophrenia prior to 13 years of age is quite uncommon, with a prevalence estimated at 1 in 10,000 patients. The estimated prevalence in adolescents (ages 13 through 17 years) is about 0.5%. Compliance problems that make a depot formulation attractive in adults are less common in the pediatric population because medication is generally administered by a parent, guardian, or caregiver. Relapse and hospitalization rates are under 10% in children and adolescents with schizophrenia. Clinical practice guidelines for the treatment of schizophrenia in children and adolescents recommend the use of oral antipsychotics, with only limited use of depot preparations.

Regarding NDA 217006, we are waiving the pediatric studies requirement for this application on the basis that studies would be unfeasible or highly impractical for both

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

indications (schizophrenia and maintenance monotherapy treatment of bipolar I disorder). In pediatric patients 0 to 9 years of age with bipolar I disorder, and 0 to 12 years of age with schizophrenia the condition has a very low prevalence. In pediatric patients 10 to 17 years of age with bipolar I disorder, and 13 to 17 years of age with schizophrenia, long-acting antipsychotic injections are unlikely to be used in a substantial number of pediatric patients; therefore, it is not feasible to conduct necessary studies in a sufficient number of pediatric patients.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry, *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)).

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact LCDR Jasmeet Kalsi, Regulatory Project Manager, at Jasmeet.Kalsi@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Bernard Fischer, MD
Deputy Director
Division of Psychiatry
Office of Neuroscience
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Instructions for Use
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BERNARD A FISCHER
03/28/2025 08:54:53 AM